Transcript
  • 7/26/2019 Cardio-Vascular an Vi

    1/19

    BOLILE

    APARATULUI

    CARDIO-VASCULAR

  • 7/26/2019 Cardio-Vascular an Vi

    2/19

    A.Obstrucia fuxuluisangvin cerebral

    Ateroscleroz; embolii; neoplzii; tromboz;tr!mtisme

    B.CardiopulmonareB"#Aritmii cr$iceB#%#Ostr!c&ii

    Br$iritmii' bloc!ri cr$ice;Sin$rom br$icr$ie-tr(icr$ie;

    Sincop )sopresore;*ipersensibilitte sin!s!l!i croti$in;

    T(iritmii' t(icr$ie s!pr)entric!lr;Sin$rom t(icr$ie-br(icr$ie;

    T(icr$ie )entric!lr;Stenoz ortic s! p!lmonr;

    *ipertro+e simetric;Tmpon$ cr$ic, nomlii conenitle $ecor$ c! .!nt $rept-st/n

    C.Presiunea sangvinC#"#Sc$ere $ebit!l!icr$icC#%#Sc$ererezisten&ei peri0erice

    C#"#"#Sc$ere 0rec)en&ei cr$iceC#"#%#Sc$ere )ol!m!l!i btie 1sc$ere contrctilit&ii b1sc$ere )ol!m!l!i circ!lnt'

    (ipo)olemie;(emorie; .oc; sincop t!sien;(ipotensi!ne post!rl;me$icmente )so$iltoreC#%#"#Vsc!lr' (iper)entil&ie

    C#%#%#Sc$ere stim!lrii simptice' en&ibtblocn&i $renerici; *ipotensi!ne

    post!rl; Sincop )so$epresore etc#D.Metabolice D#"#Sc$ere presi!nii C!ze cr$iop!lmonre

    Etiologia sincopei2$!p Ettiner, "334 cit# $e BR5SLA6U, %77"1

  • 7/26/2019 Cardio-Vascular an Vi

    3/19

    emiologie Elemente de diagnostic

    Examen general Obosel

    Curba respiratorie Dispnee, t(ipnee, cinoz, ortopnee!oc precordial Cre.tere 0rec)en&ei

    Ascultaie cardiac Diro+lrioz' s!8! $!bl!, $i+cil $e $esci0rt 20ono1Stenoz' s!8! sistolic $e stenoz p!lmonr 2proiec&interior s!b triceps .i intrre /n piept1

    Ascultaie pulmonar 9omote s!pr$!te, comple:e .i )rite pe prc!rs!le)ol!&iei

    "adiogra#e lateral Diro+lrioz' $imin!re importnt l!minii bron.ice,bron(opne!monie obstr!cti)Stenoz' (iperclritte p!lmonr

    Electrocardiogram T(icr$ie, P cresc!t .i sci&it, c!rb RS s! RS, ST /nlt

    s! s!b$ecltEc$ilibru acido%ba&ic Aci$oz, poi lcloz respirtorie mortl

    'epatomegalie -l

  • 7/26/2019 Cardio-Vascular an Vi

    4/19

    emiologie uspiciune de ,CD uspiciune de ,cD asociatcu ,cs

    Examen general r elemente speci+ce OboselCurba respiratorie orml Pert!rbt $e- l!n!l !nei Ics

    !oc precordial

  • 7/26/2019 Cardio-Vascular an Vi

    5/19

    emiologie uspiciune mic uspiciune mare Diagnostic decertitudine

    / 4 7 8Examen general Obosel proresi) l

    e0ortT!se c(intos,emetiznt noct!rn +

  • 7/26/2019 Cardio-Vascular an Vi

    8/19

    :ipul e(u&iunii Etiologia Elemente caracteristice

    S/ne "#T!morile bzei cor$!l!i%#Alte neoplzii2metsttice1G#R!pt!r tri!l!i st/nF#Tr!mtisme4#Tr!me itroene

    De obicei l rse brc(ice0le,peste )/rst $e H ni, s/neneco!ltDe obicei l msc!li $in rsemici, peste H niP!nc&ie s! cteterism cr$ic

    Trnss!$t "#Ins!+cien& cr$icconesti)%#*ipoproteinemieG#Sec!n$r, (erni$i0rmticperitoneopericr$ice

    E0!zi!ne rreori $etectbil le:men +zic s! r$ioloic

    E:s!$t "#En0!zi!ne pericr$ic

    i$ioptic benin%#Pericr$it septic

    Lic(i$ sero-sn)inolent, c!lore

    )i.nie, neco!lbilE:s!$t seros /n bol Crre .ileptospiroz; sn)inolent /nt!berc!loz s! socit c!ple!rit .i cocci$ioi$omicoz

    Diagnosticul di(erenial -n e(u&iunile pericradice la c-ine2$!p Ettiner .i S!tter, "3>7 cit# De M*ERMARIU, "3341

    i i di( i l i i - $i # i dil i di l i i

  • 7/26/2019 Cardio-Vascular an Vi

    9/19

    peci#care Cardiomiopatia'ipertro#e Dilataie

    imptome-$ispnee;-tromboembolie;

    -ptie;-0rec)en& cr$ic cresc!t;-zomote cr$ice intense;-e$em p!lmonr 2lic(i$ /nc)itte ple!rl1;

    -$ispnee;-tromboembolie;

    -ptie r);-0rec)en& cr$ic cresc!t;-zomote cr$ice $imin!te-lic(i$ /n c)itte ple!rl;

    E;< -t!lb!rri $e con$!cere;-ritmii;

    -ritmii

    Ecocardiogra#e

    -cre.tere )ol!m!l!i peretel!icr$ic;-perete inter)entric!lr cresc!t;-sept cresc!t;-c)itte )entric!l!l!i st/neste mrit

    -$ilt&ie;-perete inter)entric!lr s!b&it;

    Modi#cri

    mor(opatologice

    -(ipertro+ m!.c(ilor

    )entric!l!l!i st/n;-)ol!m!l tri!l!i st/n cresc!t;-tromboembolie rteril;

    -$ilt&i triilor .i )entric!lilor;

    -tromboembolie rteril;

    :"A:AME=: -Propnol ' 7,4-",7 m=N m#c#,per os;-!rosemi$ ' 7,4-%,% m=Nm#c#, i#)#;-C to ril ' 7 4-" m N m#c#

    -Propnolol ' 7,4-",7 m=N m#c#, per os-!rosemi$ ' 7,4-%,% m=N m#c#,per os, i#)#;-Cptopril ' 7,4-" m=N m#c#, per os;-Dio:in ' $oz ini&il ' 7,77F m=N m#c#, peros2$i)izt /n $o! pr&i1-$oz $e /ntre&inere ' 7,77Gm N m#c# er os $i)izt /n $o! r i

    Diagnostic di(erenial >i terapie -n $ipertro#a >i dilataia cardiac la pisic2$!p ?$!s ?elin$ .i col#, "33G, prel!crt $e ?O@, %771

  • 7/26/2019 Cardio-Vascular an Vi

    10/19

    ufuri cardiace emnevascular

    e

    emnepulmon

    are

    Diagnostic

    topogra#c

    Diagnosticde boal

    :imp deapariie

    ,ntensitate

    :imbru oc depercepi

    e

    Propagare

    / 4 7 8 ? 6 2 1 0

    Sufuldiastolic

    ?e$ie

    ?e$ie

    D!lce

    D!lce

    ocr!lortic

    ocr!lp!lmonr

    Pecroti$

    -

    P!ls

    rterilsltre&

    -

    -

    D

    Ins!+cien& orticIns!+cien

    &p!lmonr

    S!8!ri

    en$ocr$iceornice '

    en$ocr$ite2cronice1 .i

    )icii)l)!lre $elt nt!r

    Suful

    presistolo

    c

    Slb

    Slb

    D!r

    D!r

    ocr!ltric!spi$

    ocr!lmitrl

    Spre )/r0

    Spre )/r0

    lebectzie;P#)#

    neti)e:ert

    P##nemo$i+

    -

    D

    Stenoztric!spi$i

    n

    Stenozmitrl

    S!8!rien$ocr$ice0!nc&ionle '

    $ilt&iecr$ic,

    r!pt!ri s!(ipotonie cor$elor

    ne e cr er e agnos c n va vu opa e cron ce2$!p BR95 .i col#, "3H"1

  • 7/26/2019 Cardio-Vascular an Vi

    11/19

    / 4 7 8 ? 6 2 1 0

    Sulul

    sistolic

    ?e$ie

    ?e$ie

    ?re

    ?e$ie

    D!lce

    D!lce

    D!r

    D!r

    ocr!ltric!spi$ocr!lmitrl

    ocr!lortic

    ocr!lp!lmonrei

    Spre )/r0

    Spre )/r0

    Pe croti$

    -

    P#)# poziti) '

    8ebectzie

    P## mo$i+cts! mic

    P## $!r, mic,lent

    -

    -

    D

    -

    D

    Ins!+cien&tric!psi$

    Ins!+cien&mitrlStenozortic

    Stenozp!lmonr

    S!8!rien$ocr$ice0!nc&ionle '

    $ilt&iecr$ic,

    r!pt!ri s!(ipotonie

    cor$elor s!m!.c(ilor

    ppilri cre+:ez )l)ele

    Sulul

    sistolic

    orteslb

    D!lce

    n 0r0ocrelormobile,

    intermitente

    - - - -

    S!8!ri/n.eltore '

    nemie,c.e:ie, stri0ebrile, $!pe0ort!ri mri

    etc#

    Sulul

    sistolic

    Di0erit D!lcen 0r

    0ocrelor,mi

    0rec)entspre bz

    cor$!l!i

    - - - -

    S!8!ri $in

    nomliicr$iceconenitle 'persisten&cnl!l!irteril,

    !rii Botllo, ori+ci!l!i

    inter)entric!lretc#

  • 7/26/2019 Cardio-Vascular an Vi

    12/19

    e&iunea "A " A Aort MPA Circ. P C Alte caracteristici/ 4 7 8 ? 6 2 1 0 /5 //

    ,nsu#cie

    namitralei

    Pote + sec!n$r

    cr$ioptiei, en$ocr$itelors! .!nt!l!i $rept-st/n

    teno&aaortic

    ?e$istin lrit-0rec)ent/nt/lnit

    ,nsu#cienaortic

    C!zt $e en$ocr$it s!bol conenitl

    ,nsu#cientricuspidian

    Pote + sec!n$rcr$iomioptiei, in0#Przitre c! se$i! cr$ic,stenozei p!lmonre

    teno&apulmonar

    De)iere pe:!l!i, similrc! LV*

    :etralogia allot

    Pozi&i ortei este crnil.i pote lri me$istin!l

    De(ectseptalatrial

    Menerlizrecr$iomeliei $c esteprezent VSD

    Diro#lario&

    Artere p!lmonre lri,in+ltrte p!lmonre

    Aspecte radiogra#ce tipice -n bolile cardiace)$!p QirN .i col#, "337; elson .i Co!to, "333 cit# $e ?O@, %77+

  • 7/26/2019 Cardio-Vascular an Vi

    13/19

    / 4 7 8 ? 6 2 1 0 /5 //Persistenacanaluluiarterial

    E$em!l p!lmonr este0rec)ent /nt/lnit

    De(ectseptalventricular)D+

    Aspectele)riz#Pote +consecin& $e0ect!l!ien$ocr$il 2l pisic1

    Cardiomiopatie$ipertro#c

    Ape: $e)it, e$emp!lmonr, colec&ieple!rl

    Cardiomiopatiecongestiv)dilataie+

    Colec&ie ple!rl,e$em p!lmonr0rec)ent /nt/lnit

    E

  • 7/26/2019 Cardio-Vascular an Vi

    14/19

    ubstaa =ume despecialitate

    ,ndicaii Posologie

    / 4 7 8Amiodaron Cr$rone ibril&ie !ric!lr "-",4 m=N=zi, $e F ori, per

    osAprindin iborn T!lb!rri $e ritm )entric!lr G-4 m=N=zi, /n % prize, per

    osAtenolol Tenomine T!lb!rri $e ritm

    s!pr)entric!lrCr$iomioptie (ipertro+c*ipertiroi$ie

    7,4 m=N=zi

    Benzilthiouracil Bs$ene *ipertiroi$ie2pisic1 "47 m=zi 2" spt#1, poi,"77 m=zi, /n G prize, per os

    Bepridil Cor$i!m estbilite estbilitCaptopril Lopril Ins!+cien& cr$ic "-4 m=N=zi, /n G prize, per

    osCarbimazol eomerczole *ipertiroi$ie2pisic1 "4 m=zi 2" spt#1, poi "7

    m=zi, /n G prize, per os

    Cibenzolin Ciprln T!lb!rri $e ritm rezistente llte me$icmente

    4 m=N=zi, /n G prize, per os

    Digitalin Diitline nti)elle Ins!+cien& cr$iccomptibil c!(ipocontrctilitte

    7,74-7," m=N, /n % prize,per os

    Digoxin Dio:ine coro:ine Ins!+cien& cr$icT!lb!rri $e ritm

    s!pr)entric!lrCr$iomioptie

    7,7"-7," m=N=zi, /n % prize2pisic1

    7,7"> m=N=zi, /n % prize,per os 2c/ine1

    ,ndex terapeutic -n cardiopatiile carnivorelor)$!p M(erri!, "334 cit# $e ?O@, %77+

  • 7/26/2019 Cardio-Vascular an Vi

    15/19

    / 4 7 8Dobutamin Dob!tre: 6oc cr$ioen

    P!se! c!t $e ins!+cien&cr$ic conesti)

    4-"4 !=N=min#, i#)#, $il!t /nsol# l!cozt, izotonic

    Enalapril Renitine Ins!+cien& cr$ic 7,4 m=N=zi, per osFlecainid lecine T!lb!rri $e ritm rezistente l

    lte me$icmente4 m=N=zi, /n % prize, per os

    Flunarizin Sibeli!m Tromboembolie 2pisic1 " m=N=zi, /n % prize, per osFurosemid Lsili: Is!+cien& cr$ic 2$i!retic1 F m=N=zi, /n % prize, poi %

    m=N=zi, /n % prize, tot l %zile, per os 2pisic1H m=N=zi, /n % prize, poi Fm=N=zi /n % prize 2c/ine1

    Heparin r:iperine Tromboembolie 2pisic1 "77 UI=N=zi, s#c#, se re/noiexiletin ?e:itil T!lb!rri $e ritm )entric!lr " m=N=zi, /n G prize, per osilrinon Inocor 6oc cr$ioen 7,4 m=N=zi, i#)#, % inec&ii!icardipin Lo:en estbilite estbilit!iedipin A$lte Cr$iomioptie (ipertro+c "m=N=zi, /n % prize, per os"uabain !bine Diitlizre $e !ren& 7,7" m=N, i#)##rocainamid Pronestl T!lb!rri $e ritm )entric!lr H-%7 m=N=zi, /n G prize, per

    os

    #ropaenon Rt(mol T!lb!rri $e ritm rezistente llte me$icmente

    4 m=N=zi, /n G prize, per os

    #ropanolol A)locr$l Cr$iomioptie (ipertro+cT!lb!rri $e ritms!pr)entric!lr*ipertiroi$ie

    7,-G m=N=zi, /n G prize, peros

    $rinitine Lenitrl

    perc!tne

    Ins!+cien& cr$ic

    2)so$ilttor1

    G ori=zi, l bz !rec(ii

    %erapamil Isoptine ibril&ie !ric!lr "-",%H m=N=zi, /n F prize, per

  • 7/26/2019 Cardio-Vascular an Vi

    16/19

    Medicamenteantiaritmice

    Pre&entare Productor

    / 4 7

    CAA , )blocanteale canalelor desodiu+Li$ocin

    Uz )eterinr-%7 m=ml 2% 1, sol# in#Uz !mn-%7 m=ml 2% 1, sol# in# Di0erite 0ormeilocin 2Astr, estboro!(,?A1

    Procinmi$ %47, G>4 .i 477 m, tblete .i cps!le"77 .i 477 m=ml, sol# in#

    Pronestl 2Bristol ?res S!ibb,Princeton, W1

    Procinmi$ 2retr$1 %47, 477, >47 .i "777 m, tblete Pronestl 2Bristol ?res S!ibb,

    Princeton, W1S!l0t $e !ini$in2stn$rt1

    %77 .i G77 m, tblete Di0erite 0orme

    S!l0t $e !ini$in 2retr$1 G77 m, tblete !ini$e: E:tentbs 2A#*#Robins, Ricmon$, VA1

    Ml!cont $e !ini$in2retr$1

    G%F m, tbleteH7 m=ml, sol# in#

    !inl!te D!r-Tbs 2Berle:Lbortories, ne, W1

    !inlnLnnet, P(il$elp(i, PA 2EliLill, In$inopolis, I1

    Polilct!ront $e!ini$in

    %>4 m, tblete 2ec(i)lent %77 m$e s!l0t $e !ini$in1

    Cr$io!in 2P!r$!e re$ericN,orXlN, CT1

    Tocini$ F77 .i 77 m, tblete Tonocr$ 2?ercN, est Point, PA1?i:elitin "47, %77 .i %47 m, cps!le ?e:itil 2Boe(riner Iei(eim

    P(rmce!ticls, Ri$e+el$, CT1enitoin 47 m=ml, sol#in# Dilntin 2PrNe-D)is, ?orris

    e ca e an ar m c)$!p ELSO .i COUTO, "333+

  • 7/26/2019 Cardio-Vascular an Vi

    17/19

    / 4 7

    CAA a ,,%a )blocantebeta%adrenergice+Proprnolol

    "7, %7, F7, 7, H7, 37 m,tblete" m=ml, sol#in#F, H .i H7 m=ml, sol#orl,

    cps!le

    In$erl 2et(-AerstLbortoires, P(il$elp(i, PA12Ro:ne Lbortoires, Col!mb!s,O*1

    In$erl LA 2et(-AerstLbortoires1Atenolol %4, 47 .i "77 m, tblete

    4 m="7 ml, sol#in#Tenormin 29enec, ilminton,DE1

    Esmolol "7 m=ml .i %47 m=ml, sol#in# Bre)ibloc 2D!Pont ?ercN,ilminton, DE1

    CAA a ,,,%a )blocante

    ale canalelor de potasiu+Bretli!m

    47 m=ml, sol#in# Bretlol 2D!Pont Criticl Cre,

    ilminton, DE1

    Amio$rone %77 m, tblete47 m=ml, sol#in#

    Cr$rone 2et(-AerstLbortoires, P(il$elp(i, PA1

    Sotlol H7, "7 .i %F7 m, tblete Betpce 2Berle:, ne, W1

    CAA a ,%a )blocante

    ale canalelor de calciu+Verpmil

    F7, H7 .i "%7 m, tblete

    4m=% ml, sol#in#

    Cln 2Serle, C(ico, IL1

    Isoptin 2Qnoll P(rmce!ticl,(ippn, W1

    Diltizem G7, 7, 37 .i "%7 m, tblete4m=ml, sol#in#

    Cr$izem-CD 2?rion ?errelDoX, Qnss Cit, ?O1

    Diltizem "%7, "H7, %F7 .i G77 m,cps!le"%7, "H7 .i %F7 m, cps!le

    Cr$izem-CD 2?rion ?errelDoX1Dilcor R 2R(one-Po!lencRorer, Collee)ille, PA1

  • 7/26/2019 Cardio-Vascular an Vi

    18/19

    A=:,CO,=E"

  • 7/26/2019 Cardio-Vascular an Vi

    19/19

    =ume generic Denumire comercial Do&a )interval+

    Benzopril Lotensin 7,%4 m>N, per os, %F ore 2c/ine1

    Cptopril Cptopril 7,4-% m=N, per os, H-"% oreEnlpril Encr$ 7,%4-7,>4 m=N, per os, "%-%F ore

    Lisinopril Prini)il 7,F-" m=N, per os, "%-%F ore 2c/ine1

    Rmipril Altce 7,4 m=N, per os, "%-%F ore 2c/ine1

    Atenolol Tenormin ,%4-"%,4 m, per os, "%#%F ore 2pisic1"-% m=N, per os, "%-%F ore 2c/ine1

    Proprnolol In$erl 4-"7 m=N, per os, H-"% ore 2pisic14-H7 m=N, per os, H-"% ore 2c/ine1

    Przosin 2blocrereceptor!l!il0$reneric1

    ?inipress 7,%4-" m=N, per os, H-"% ore 2pisic17,%4-" m=N, per os, H-"% ore 2c/ine1

    Amlo$ipine or)sc 7,%4 m, per os, %F ore 2pisic1

    Diltizem Cr$izem >,4-"4 m, per os, H-"% ore 2pisic17,%4-% m=N, per os, H-"% ore 2c/ine1

    Verpmil Isoptin " m=N, per os, H-"% ore 2pisic1

    Diltizem Cr$izem DC "7 m=N, per os, %F ore 2pisic1

    *i$roclortrizi$ *$roD!ril %-F m=N, per os, "% ore

    !rosemi$ Lsi: "-F m=N, per os, H-"% ore

    Spironolcton Al$ctone %-F m=N, per os, %F ore

    edicamente (olosite -n terapia anti$ipertensiv la c-ine >i pisic)$!p P*ILIP, "333+


Top Related